Aurinia Pharmaceuticals Inc. Annual Income Tax Expense (Benefit) in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Aurinia Pharmaceuticals Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2018 to 2023.
  • Aurinia Pharmaceuticals Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $756K.
  • Aurinia Pharmaceuticals Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $2.25M, a 40.5% increase year-over-year.
  • Aurinia Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2023 was $551K, a 69.9% decline from 2022.
  • Aurinia Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2022 was $1.83M, a 141% increase from 2021.
  • Aurinia Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2021 was $760K.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $551K -$1.28M -69.9% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-15
2022 $1.83M +$1.07M +141% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-15
2021 $760K +$854K Jan 1, 2021 Dec 31, 2021 10-K 2024-02-15
2020 -$94K -$238K -165% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $144K +$71K +97.3% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $73K Jan 1, 2018 Dec 31, 2018 10-K 2021-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.